|D045169||Severe Acute Respiratory Syndrome NIH||0.04|
|D018352||Coronavirus Infections NIH||0.03|
There is one clinical trial.
This is an adaptive, randomized, double-blinded, placebo-controlled, Phase II/III study conducted to evaluate the effect of SCTA01 on participant survival and clinical efficacy in participants with severe COVID-19 admitted to high dependence or ICUs. The study duration of subject participation will be up to: 120 days Participants will receive a single intravenous (IV) infusion of SCTA01 at Treatment day 1. Follow up visits will be up to 120 days or early withdrawal visit.
Description: The mortality rates in placebo and treatment groups regardless of the cause of death.Measure: All-cause mortality rate at D29 Time: Day 29
Description: The mortality rates in placebo and treatment groups regardless of the cause of death.Measure: All-cause mortality rate at Day 60 Time: Day 60
Description: The number of days from randomization to discontinue MV supportMeasure: Time to discontinue mechanical ventilation (MV) at Day 29 Time: Baseline through Day 29
Description: The number of days from baseline to two categories decreases on World Health Organization (WHO) 10-Point Ordinal Scale at Day 29.Measure: Time to improvement of two categories on WHO 10-Point Ordinal Scale from baseline at Day 29 Time: Baseline through Day 29
Description: The number of days from randomization to discontinue supplemental oxygen supportMeasure: Time to discontinue supplemental oxygen at Day 29 Time: Baseline through Day 29
Description: The number of days from randomization to subject's discharge from hospital.Measure: Time to hospital free at Day 29 Time: Baseline through Day 29
Description: Change from baseline in viral sheddingMeasure: Change from baseline in viral shedding as measured by quantitative reverse transcription polymerase chain reaction (RT-qPCR) Time: Baseline through Day 29
Description: SAEs collected from Day 1 to Day 120Measure: SAE Time: Day 1 through Day 120
Description: ADA will be tested at Day 29 and Day120 after SCTA01/placebo administrationMeasure: Anti-drug antibody (ADA) Time: Day 29, Day 120
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports